Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 79 Publications

17 Customer Reviews

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 NYqxTJRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\1SZBvPCCm Mn3zTWM2OD13LkewOUAh|ryPIB?= MmrsNVg2PTl4MUO=
KP6.3 M{jpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjIdYM1KGR? M4\6d2lEPTB;MUCuOFI5KM7:TTC= M{nLdlE5PTV7NkGz
KP7.7 NInCZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSx[2tlPCCm MYjJR|UxRTV5IH7NJC=> NWXxXIZtOTh3NUm2NVM>
KB2P3.4 NUnKbJp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC0JIQ> NIDCR|VKSzVyPUGyOEBOKA>? M1nleVE5PTV7NkGz
KB2P1.21 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[0JIQ> MVfJR|UxRTh7MEegcm0h M3;2U|E5PTV7NkGz
U373-MG NIfWU4REgXSxdH;4bYMhSXO|YYm= NGj0VVkyKM7:TTC= NXHZPWdKOjRiaB?= NIDuUWtKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NGOzeXoyQDl3NEexNi=>
T98G NVLH[W44S3m2b4TvfIlkKEG|c3H5 M2DiTlEh|ryPIB?= MmDkNlQhcA>? NV61[Ws4UW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= Ml6yNVg6PTR5MUK=
U87-MG MlrmR5l1d3SxeHnjJGF{e2G7 Mn\GNUDPxE1i NVfwVmhWOjRiaB?= M3zrOmlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? NITTOpMyQDl3NEexNi=>
UVW MlzVR5l1d3SxeHnjJGF{e2G7 MlzLOVAxKG6P MnPFNlQhcA>? MkPDTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? M1LDNVE5QTV2N{Gy
HeLa NEfqUHVHfW6ldHnvckBCe3OjeR?= NFT4RXA2ODBibl2= M{TLS|QhcA>? Mm\KR4F2e2W|IHGgcY9l\XO2IHTlcIF6KGmwIILlbo9qdmmwZzDv[kBz[WSrYYTpc44ucW6mdXPl[EBFVkFiYoLlZYt{ NF7SenoyQDl3NEexNi=>
HeLa MmDqSpVv[3Srb36gRZN{[Xl? M1j2OFEh|ryPIB?= MorDNlQhcA>? NIPodFRGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= NWL6TJkzOTh7NUS3NVI>
T98G MnnUSpVv[3Srb36gRZN{[Xl? M3juNlEh|ryPIB?= NGXYNmQzPCCq NGi0NG5GdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= MoDoNVg6PTR5MUK=
L3 NE\vNpBEgXSxdH;4bYMhSXO|YYm= NIH6fXM2KM7:TTC= NUPx[mo1QTZiaB?= MVLEUXNQ NHTDd2lUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> MofLNlAyOjR2NUm=
Granta-519 MV7DfZRwfG:6aXOgRZN{[Xl? M4nDOlUh|ryPIB?= NGD5N2s6PiCq NXjwXIVkTE2VTx?= M3nYVXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? NUfUNWU6OjBzMkS0OVk>
BT MkXCR5l1d3SxeHnjJGF{e2G7 NWPzVWlsPSEQvF2g MYC5OkBp M3K3TGROW09? MmHsV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? M2TVN|IxOTJ2NEW5
UPN2 NUL6fJp7S3m2b4TvfIlkKEG|c3H5 NFLKV|Q2KM7:TTC= MYS5OkBp MVfEUXNQ MUXTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MkPqNlAyOjR2NUm=
HBL-2 M4TFb2N6fG:2b4jpZ{BCe3OjeR?= NVrNZXN4PSEQvF2g MnHpPVYhcA>? M2G0RWROW09? MWXTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MYmyNFEzPDR3OR?=
JVM-2 M2XLTGN6fG:2b4jpZ{BCe3OjeR?= NVK2b|V4PSEQvF2g M4HmWFk3KGh? NVPzW|drTE2VTx?= M{ftWnNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? NWmzWndvOjBzMkS0OVk>
Z138 M{fsRmN6fG:2b4jpZ{BCe3OjeR?= NUfGdW4zPSEQvF2g NXm4R5U1QTZiaB?= MmLlSG1UVw>? M4\rfXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? MWWyNFEzPDR3OR?=
RWPE MXTJcpZie2m4ZTDBd5NigQ>? NV3QOndMOjVizszN MmDiOFghcA>? MljNSG1UVw>? M3nEc3Nq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> M1vt[VIyPTd3OE[1
VCaP NXj1W|JpUW64YYPpeoUhSXO|YYm= NWS2b4tzOjVizszN NUnaPHN7PDhiaB?= NFP0SIdFVVOR MmHQV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> NXrUNFM6OjF3N{W4OlU>
Mouse H2AX−/− ES Cells NXjmTGxjS3m2b4TvfIlkKEG|c3H5 MV:yMlUh|ryP NIjPNHMzOCCq MmjMV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs M1TGXlI{OzV3NEi5
Mouse ATM−/− ES Cells M1vRTGN6fG:2b4jpZ{BCe3OjeR?= NY\GVGxGOi53IN88US=> NIr4O2szOCCq M3znVHNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> M1Pa[|I{OzV3NEi5
H1650 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqyNEDPxE1? MVOxOFQhcA>? NUnC[pRRUUN3ME2xOU41PyEQvF2= MYSyN|I{QThyOR?=
H1650PTEN+ MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3ERXQzOCEQvF2= NYf5ZXhzOTR2IHi= NWDCU21oUUN3ME21NE45OyEQvF2= MnX1NlMzOzl6MEm=
PC-9 M1fPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXeyNEDPxE1? MXuxOFQhcA>? M{PQVWlEPTB;NT64PEDPxE1? Mn3SNlMzOzl6MEm=
PC-9PTEN− MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzlVXlGOjBizszN Mn:2NVQ1KGh? M{DKeGlEPTB;Nj61NkDPxE1? MmDXNlMzOzl6MEm=
MDA-MB-231 M{LqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVG1JIRigQ>? NXvm[Vd{UUN3ME22Mlkh|ryP M3rHWFI{PzZyNEm2
MDA-MB-468 Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjZOUBl[Xl? MkLOTWM2OD13LkCg{txO M1T6ZlI{PzZyNEm2
BT20 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LhcFUh\GG7 NG\BcFVKSzVyPUeuO{DPxE1? MUSyN|c3ODR7Nh?=
HCC1143 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjXW4E2KGSjeR?= MWrJR|UxRTFzLkGg{txO MoDoNlM4PjB2OU[=
HCC1937 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXq1JIRigQ>? MmDVTWM2OD1zMj62JO69VQ>? NHfUfJMzOzd4MES5Oi=>
Hs578t NVnwdYc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTYOUBl[Xl? M{TDSWlEPTB;NT62JO69VQ>? M2rvO|I{PzZyNEm2
Hs578t(si) NVH5cW1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT4PHVEPSCmYYm= M125O2lEPTB;Nz61JO69VQ>? NYHSdYxHOjN5NkC0PVY>
BT474 NIG1PI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17rOFUh\GG7 M{fL[2lEPTB;MUmuPEDPxE1? MkDGNlM4PjB2OU[=
JIMT1 MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLVOUBl[Xl? MWfJR|UxRTdwNzFOwG0> MYSyN|c3ODR7Nh?=
SKBR3 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWW1JIRigQ>? M3KzR2lEPTB;MUGuNUDPxE1? MVKyN|c3ODR7Nh?=
SUM159 NGTDU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zOUVUh\GG7 MV\JR|UxRTRwMjFOwG0> MVKyN|c3ODR7Nh?=
CAMA1 NFv0OXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O1bFUh\GG7 MnrVTWM2OD1zNT64JO69VQ>? NITFNIMzOzd4MES5Oi=>
MCF7 M4PPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7MSZc2KGSjeR?= MV3JR|UxRTVwODFOwG0> NV;NZ49uOjN5NkC0PVY>
T47D NHixcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LyZlUh\GG7 MVTJR|UxRTlwNjFOwG0> NFexTpczOzd4MES5Oi=>
HCT116 NIX1[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTkfmFXOTByIN88US=> MkL4OFghcA>? MV;EUXNQ MW\JR|UxRTJwNTFOwG0h NYfjWXlSOjR3N{e5OFE>
SW1116 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\wW3AyODBizszN MUW0PEBp MkHXSG1UVw>? MXHJR|UxRTFyMDFOwG0> NV\Y[4tmOjR3N{e5OFE>
HT29 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\6eJFGOTByIN88US=> M4fXOlQ5KGh? MkHzSG1UVw>? M3TUWGlEPTB;MUSuO{DPxE1? MnnKNlQ2Pzd7NEG=
LoVo NHHkOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSxNFAh|ryP MWO0PEBp Mn24SG1UVw>? MmTPTWM2OD1zMz60JO69VQ>? NI\nRoozPDV5N{m0NS=>
HCT-15 NHzPcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXixNFAh|ryP M3;HWFQ5KGh? MmLYSG1UVw>? Ml;KTWM2OD1zMDFOwG0> M{PQNVI1PTd5OUSx
SW48 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXxNVAxKM7:TR?= MUC0PEBp M4TNTGROW09? MnXKTWM2OD17LkWg{txO NXrEVVFxOjR3N{e5OFE>
C-1 NF\sSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPsZm0yODBizszN NIrofJY1QCCq NHfaelNFVVOR NVjZSIVJUUN3ME23MlYh|ryP NEXMeZAzPDV5N{m0NS=>
RKO NFqzOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLaNVAxKM7:TR?= NU[xUlFOPDhiaB?= M37hc2ROW09? NE\QOnRKSzVyPUWuPUDPxE1? MVqyOFU4Pzl2MR?=
HCT116 M4CxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoftNVAxKM7:TR?= MU[0PEBp MlvXSG1UVw>? MmTEVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MWOyOFU4Pzl2MR?=
SW1116 NGLVSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnrXI95OTByIN88US=> NGrJfJk1QCCq M1zQOmROW09? M33oVHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NUnxcZE2OjR3N{e5OFE>
HT29 M4\me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;6RlExOCEQvF2= MmDnOFghcA>? MV3EUXNQ M1LsdHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? M2j6VlI1PTd5OUSx
LoVo M4TQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfkR3RGOTByIN88US=> NFTmNZU1QCCq NUPsT3JETE2VTx?= NUS0b3A6WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NYPB[oR7OjR3N{e5OFE>
SW48 M2HZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfad28yODBizszN NVXOd5Z4PDhiaB?= M2nCVmROW09? NVn1VZJZWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MUSyOFU4Pzl2MR?=
C-1 M1jzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;WfFlrOTByIN88US=> NIeyeo41QCCq NE\OT3JFVVOR MVLQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MnfrNlQ2Pzd7NEG=
RKO NIDCeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj2XmMyODBizszN NYTSV21pPDhiaB?= MWTEUXNQ MnfJVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? NUX0[IZiOjR3N{e5OFE>
HCT116 MnLPSpVv[3Srb36gRZN{[Xl? NVPGc29WOTBibl2= NHTVVWwyOiCq M4DIZ2ROW09? M37aPWlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1|OB?= MY[yOFU4Pzl2MR?=
HT29 NIrOPVJHfW6ldHnvckBCe3OjeR?= M4LnO|ExKG6P NWXZe4EyOTJiaB?= NFzseHNFVVOR M3u5SGlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1|OB?= NUnke2dEOjR3N{e5OFE>
TE-6 MWLGeY5kfGmxbjDBd5NigQ>? NEP4Voo2KM7:TTC= NGTC[ngyOiCq NWDBfFNGTE2VTx?= MlHZTY5lfWOnczDHNk9OKGG{cnXzeC=> M2PkelI1OjF7MU[0
TE-6 NXPZcHZCTnWwY4Tpc44hSXO|YYm= MXq1JO69VSB? M4HCU|I1KGh? M2S5XWROW09? NHvGeZVKdmO{ZXHz[ZMhcW5iZH;1ZoxmKHO2cnHu[EBjemWja4OgLGRUSnNr NHzYXJUzPDJzOUG2OC=>
Hep3B MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7tOFAh|ryPIB?= NHvXPW44OiCq NEK2cVVFVVOR MVPTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=> M1PUOVI2ODd{N{Wy
Huh7 M{jmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq0NEDPxE1i NHG3[5k4OiCq MnfLSG1UVw>? M4jneHN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS NFTLdHUzPTB5Mke1Ni=>
Hep3B NELmb5dHfW6ldHnvckBCe3OjeR?= MWO0NEDPxE1i MW[yOEBp NGfzW4lFVVOR NFztOVFKdmS3Y3XzJHJQWyCycn;keYN1cW:wIIfpeIghTEiPRWG= M3SwUFI2ODd{N{Wy
Huh7 NF\XdnpHfW6ldHnvckBCe3OjeR?= MYO0NEDPxE1i NVXHSFR4OjRiaB?= NV7C[XFqTE2VTx?= MkPOTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT NHjEeHgzPTB5Mke1Ni=>
Hep3B NGrTT45HfW6ldHnvckBCe3OjeR?= MlXhOFAh|ryPIB?= M{C3VFI1KGh? MWXEUXNQ NHjnd3JKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= MWWyOVA4Ojd3Mh?=
Huh7 M4fUTWZ2dmO2aX;uJGF{e2G7 NFvlfZQ1OCEQvF2g MVeyOEBp NE\6N3lFVVOR NVXKWph2UW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR NGLOS4IzPTB5Mke1Ni=>
SGC-7901 NYrJRYFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfnc|Y4OzEEoN88US=> NGrsOlM1QCCq M2e4VmROW09? NIW4cXVDdG:lazDvfIFtcXCuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NFnUV4czPTd4N{C3Oi=>
COLO-800 NXzWZYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwNESxOlQh|ryP NV;0V2FqW0GQR1XS
EoL-1- Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwNU[0OFYh|ryP NGfsN4lUSU6JRWK=
NCI-H209 M3znT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwOUG1OVYh|ryP Mnf3V2FPT0WU
ES1 NIC2eWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL1OFFKSzVyPUGuNVE1ODhizszN MXfTRW5ITVJ?
NKM-1 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T1UGlEPTB;MT6yOVM1PyEQvF2= NEf5T4RUSU6JRWK=
NTERA-S-cl-D1 NYDR[lFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFwM{OzOFEh|ryP MXfTRW5ITVJ?
MHH-ES-1 NWfyNZBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwNkKwOlch|ryP M2XEd3NCVkeHUh?=
ES8 NHTvUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFwN{K0NVQh|ryP MkOxV2FPT0WU
NCI-H720 MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPxNVJKSzVyPUKuNlA3QTlizszN MnXSV2FPT0WU
EW-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;IbGlEPTB;Mj6yO|U{PCEQvF2= MUTTRW5ITVJ?
D-566MG M3f4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDlZnVKSzVyPUKuOFQ2PjhizszN NWD6OolmW0GQR1XS
697 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTQTWM2OD1{Lki0NVc{KM7:TR?= MmPGV2FPT0WU
ES5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX4SIo6UUN3ME2yMlg5OTh7IN88US=> MnrWV2FPT0WU
COLO-684 NGOyW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;YNWlEPTB;Mz61NVY6PiEQvF2= M3G3[XNCVkeHUh?=
ML-2 NFnoWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m0bWlEPTB;Mz62NFA2QCEQvF2= MlPJV2FPT0WU
MC-IXC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLjWJdKSzVyPUOuOlM{QTNizszN NYTvVY84W0GQR1XS
DB NF3EdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn73TWM2OD1|Lk[1OFQ5KM7:TR?= NU\zcmg2W0GQR1XS
HCC2218 M17LNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2T0bmlEPTB;Mz63N|ExOyEQvF2= MYnTRW5ITVJ?
NCI-H510A M4X3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwOEK3NlQh|ryP NHX4ZXdUSU6JRWK=
NCI-H526 NGD3U5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPHT3g1UUN3ME2zMlg3QTV6IN88US=> M1zIPHNCVkeHUh?=
MV-4-11 NXO3d4d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL5SI9KSzVyPUSuNVM{OzRizszN NVLvTnMzW0GQR1XS
PA-1 NVfOWZZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rsOGlEPTB;ND6yOVI6KM7:TR?= M3LCXXNCVkeHUh?=
EW-22 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmzTWM2OD12LkO1PFYh|ryP NVS5eZAxW0GQR1XS
KASUMI-1 NV33SnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDQTWM2OD12LkSwNVA6KM7:TR?= NVLX[Y9RW0GQR1XS
LU-139 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfnTWM2OD12Lke1PFI6KM7:TR?= NEHhSYdUSU6JRWK=
SBC-1 NGrKN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTRwOEC5NFgh|ryP M4KyVnNCVkeHUh?=
H4 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jH[mlEPTB;ND64PVQ1OyEQvF2= MmDrV2FPT0WU
EW-11 M4TpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTVwMEiwO|Ih|ryP M4HvTHNCVkeHUh?=
NBsusSR NWjCO2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTVwMUKwOVUh|ryP NX23Zph3W0GQR1XS
RPMI-8226 NVHoTlY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfLfZZSUUN3ME21MlE2OjR2IN88US=> NXPZUpZOW0GQR1XS
DEL NUnSRo1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3CSXc5UUN3ME21MlIxODB4IN88US=> MnHPV2FPT0WU
ES4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjTWWtKSzVyPUWuOVE{QDlizszN MVfTRW5ITVJ?
GCT MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTLdYh1UUN3ME21MlU3QDV4IN88US=> MmrzV2FPT0WU
NCI-H1048 NHnp[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjvW|BRUUN3ME21Mlk4Ojd|IN88US=> MlfPV2FPT0WU
NCI-SNU-1 NGDBcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHlT3NGUUN3ME22MlAzOiEQvF2= MVTTRW5ITVJ?
ES7 NXSxcG9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1myWGlEPTB;Nj6wN|U4PyEQvF2= MWTTRW5ITVJ?
SW982 M2\3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPQTWM2OD14LkC5NVM4KM7:TR?= MX\TRW5ITVJ?
L-363 M3TJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTZwM{O5O|Qh|ryP MWfTRW5ITVJ?
HT-1080 M2\3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTZwNEm2PFMh|ryP NFPwWHpUSU6JRWK=
HAL-01 NFjHVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDucnFyUUN3ME22MlUyODlizszN NVSz[4xIW0GQR1XS
NB14 M4[1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLvTWM2OD14Lk[0NFM6KM7:TR?= M1fmcXNCVkeHUh?=
EW-13 NGnpXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17X[2lEPTB;Nj63O|QzPCEQvF2= NV7WbnZiW0GQR1XS
NY MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTZwOUS2NFUh|ryP NEnzTJpUSU6JRWK=
NCI-SNU-5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3PZ|VoUUN3ME23MlExPDN|IN88US=> M3;jR3NCVkeHUh?=
MS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnJToRKSzVyPUeuNVc1QTRizszN NGPzXmVUSU6JRWK=
EW-16 NXL3NZNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVqyO21CUUN3ME23MlMyQDZzIN88US=> MkPuV2FPT0WU
LU-65 NXjXPG1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTdwNEi0NVch|ryP NYmzUGh3W0GQR1XS
HGC-27 NW\JO4VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;le2xKSzVyPUeuO|IyPzNizszN MYXTRW5ITVJ?
CTB-1 M3XwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzF[oUzUUN3ME23Mlc3OTd3IN88US=> MWTTRW5ITVJ?
5637 NELy[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEiwTHZKSzVyPUeuPVI5PiEQvF2= M1vzc3NCVkeHUh?=
U251 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7nTWM2OD15Lkm0NFE3KM7:TR?= NHj1UnRUSU6JRWK=
HOS NH62XHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnmXmtKSzVyPUiuNlMxODdizszN M4PIXnNCVkeHUh?=
DOHH-2 M1vuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TibGlEPTB;OD6yN|U5KM7:TR?= Mm[yV2FPT0WU
EW-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq2TWM2OD16LkOwNFg5KM7:TR?= MW\TRW5ITVJ?
BV-173 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DSNGlEPTB;OD61OVU1KM7:TR?= M2XUc3NCVkeHUh?=
8-MG-BA NWi2[JVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HBSGlEPTB;OD62PFk5QCEQvF2= NUHObmVxW0GQR1XS
NB69 M3S5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{flfGlEPTB;OD63NFkzOSEQvF2= M2qzeXNCVkeHUh?=
NCI-H69 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DBWWlEPTB;OT65NFk3OSEQvF2= NFe4NGlUSU6JRWK=
RS4-11 NH;SUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETL[3ZKSzVyPUGxMlIzODhizszN MmTsV2FPT0WU
ONS-76 M1i0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFzLkK5OFch|ryP NGPsOnhUSU6JRWK=
SF539 NH3FeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFzLkS4PFkh|ryP M3PHeHNCVkeHUh?=
HuO-3N1 NX;ReWxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;DV2lEPTB;MUGuOVc6PiEQvF2= MWnTRW5ITVJ?
NCI-H1651 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPBTWM2OD1zMj6zNVE2KM7:TR?= NXHre4VZW0GQR1XS
KARPAS-45 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn6TWM2OD1zMj6zO|Yh|ryP MWDTRW5ITVJ?
SK-NEP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLuTWM2OD1zMj60OlA6KM7:TR?= NHy0W|VUSU6JRWK=
LAMA-84 NHLCXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF|LkGwPVUh|ryP NEC1fodUSU6JRWK=
NCI-H1155 MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHuTWM2OD1zMz6yPFU3KM7:TR?= NHTIcoxUSU6JRWK=
CTV-1 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1mzUGlEPTB;MUOuOFQ2KM7:TR?= MWfTRW5ITVJ?
QIMR-WIL NGT5XmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF|Lke4NVQh|ryP MkHNV2FPT0WU
H9 NXfp[G1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW4NmdKSzVyPUGzMlg1PzVizszN MV;TRW5ITVJ?
SK-MEL-1 NHnPXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH3fGxKSzVyPUGzMlk{PDdizszN Mn[yV2FPT0WU
HD-MY-Z M3vsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjqcpdqUUN3ME2xOE4xPjN5IN88US=> NG\0cItUSU6JRWK=
TI-73 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[3dWlEPTB;MUSuNlM2PiEQvF2= NVXGS3JWW0GQR1XS
JVM-3 NEnab4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;zXnRKSzVyPUG1MlU4OTZizszN MkLkV2FPT0WU
D-247MG NVXqeY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\iRZlXUUN3ME2xOU42QTNizszN NYfkTIpZW0GQR1XS
VA-ES-BJ MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrTOY9KSzVyPUG1MlYxQTdizszN NUizXG1RW0GQR1XS
NOS-1 NUPEZ5BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fENGlEPTB;MUWuOlUzOiEQvF2= NG\I[JRUSU6JRWK=
MOLT-4 NU\mU4ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID6WGhKSzVyPUG2Mlc2OiEQvF2= NH;QWplUSU6JRWK=
Mo-T NWPvS5BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr6SG9KSzVyPUG3MlA5PDlizszN M2mwTXNCVkeHUh?=
NCI-H1770 M3i4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;UOpU6UUN3ME2xO{4yPTR|IN88US=> MnrjV2FPT0WU
COLO-320-HSR M4\IV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXETnBKSzVyPUG3MlE5OjdizszN NHPwbXdUSU6JRWK=
TE-12 NUP2Z4ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLiZlR2UUN3ME2xO{44ODV2IN88US=> M3z0OHNCVkeHUh?=
NCI-H82 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXLNXZKSzVyPUG3Mlg4OjhizszN MX3TRW5ITVJ?
NEC8 NFvPfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF6LkGzNVYh|ryP MXvTRW5ITVJ?
HSC-3 M2PvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TyUWlEPTB;MUiuO|QyPCEQvF2= MULTRW5ITVJ?
NCI-H1092 NXewfY0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\RemlEPTB;MUiuO|U6PSEQvF2= M{LnRXNCVkeHUh?=
NCI-H292 M4W3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfqcHdKSzVyPUG5MlA1QDlizszN NUDHb5J3W0GQR1XS
L-428 M4Xq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnyOVVKSzVyPUG5MlU2QSEQvF2= NHm5Z3JUSU6JRWK=
LU-134-A MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G2S2lEPTB;MUmuOVczKM7:TR?= MVnTRW5ITVJ?
GI-ME-N NVLrZmZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Xsd2lEPTB;MUmuOVc1PyEQvF2= MmX6V2FPT0WU
ALL-PO Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OzN2lEPTB;MUmuOVk4OiEQvF2= M3niT3NCVkeHUh?=
D-283MED M{izfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HpOWlEPTB;MUmuPVE2KM7:TR?= NUjJVXpEW0GQR1XS
D-423MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TpSGlEPTB;MUmuPVk3PyEQvF2= NXrmNZVMW0GQR1XS
CAKI-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS4dZhKSzVyPUKwMlIzOTlizszN NHuw[GNUSU6JRWK=
ETK-1 NFzocXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJyLkK2NVUh|ryP MUfTRW5ITVJ?
G-402 M1L1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi0d4V4UUN3ME2yNE42OzN2IN88US=> NX3EN3k4W0GQR1XS
HL-60 NYrhZlkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJzLkG2NVMh|ryP NVflWHRwW0GQR1XS
A2058 MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe3cJpIUUN3ME2yNU41PDd5IN88US=> NES3[WtUSU6JRWK=
CHP-212 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf0TWM2OD1{MT65NFUyKM7:TR?= M2PUNXNCVkeHUh?=
KY821 M3zZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi2OHFrUUN3ME2yNU46PzVizszN MnnoV2FPT0WU
TYK-nu NGDz[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\kcmVKSzVyPUKyMlA3PTFizszN M1ezfXNCVkeHUh?=
JVM-2 M3za[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm3W|gyUUN3ME2yNk4zQTh|IN88US=> NYrncHpQW0GQR1XS
KU812 NGn0dnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rkV2lEPTB;MkKuO|MyOiEQvF2= MYnTRW5ITVJ?
MKN28 M4jufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;aVJFKSzVyPUKyMlkxOTVizszN MVjTRW5ITVJ?
ECC10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ|Lke0NUDPxE1? NXrle3VEW0GQR1XS
BHT-101 M1zVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXYV|l6UUN3ME2yOE4xODB6IN88US=> M1z3OnNCVkeHUh?=
DU-4475 NGHH[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknFTWM2OD1{ND6zN|M4KM7:TR?= MUjTRW5ITVJ?
769-P M1\ubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nUPGlEPTB;MkSuPFQ3PiEQvF2= MlvIV2FPT0WU
HEC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfFTGFsUUN3ME2yOU41PDVizszN NHrYPWxUSU6JRWK=
MOLT-13 NYPZRoRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ3LkWzN|Eh|ryP NFXrbWVUSU6JRWK=
8505C MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjGVI1KSzVyPUK2MlQ6PzdizszN NFnwVYpUSU6JRWK=
GB-1 MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fZO2lEPTB;Mk[uO|E4PiEQvF2= Ml7NV2FPT0WU
SF126 M1;CbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHUfGoyUUN3ME2yOk44PjR6IN88US=> NH;HPIJUSU6JRWK=
A4-Fuk NIfjd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnSWJdGUUN3ME2yO{4yOjdzIN88US=> MUjTRW5ITVJ?
OVCAR-8 NGDwOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonWTWM2OD1{Nz6xOVM6KM7:TR?= M2rENnNCVkeHUh?=
NCI-H1304 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjqflhKSzVyPUK3MlU1KM7:TR?= M4LWNXNCVkeHUh?=
GR-ST NITzd5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvxTWM2OD1{OD6wOFch|ryP M3:5bXNCVkeHUh?=
G-401 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PGZmlEPTB;MkiuOVA6PiEQvF2= NFr2d3lUSU6JRWK=
LXF-289 MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnIT4d6UUN3ME2yPE42PjVzIN88US=> M4HVZXNCVkeHUh?=
DBTRG-05MG M{jJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ6LkmyNFQh|ryP M{LMW3NCVkeHUh?=
YKG-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ7Lki2PEDPxE1? NIjvWZFUSU6JRWK=
GAMG NFOxW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnjPIhKUUN3ME2yPU46QTNizszN Mn7KV2FPT0WU
HCT-116 NUn1VJVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTNyLkC1OFgh|ryP NF33VmtUSU6JRWK=
S-117 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fNRWlEPTB;M{GuNlI2PyEQvF2= M33xdXNCVkeHUh?=
NCI-H1693 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\qTFVKSzVyPUOzMlY2PDJizszN NGPt[G9USU6JRWK=
A427 NF\SWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nSVWlEPTB;M{OuPVk4PiEQvF2= MX;TRW5ITVJ?
HT-29 NU\xbZpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXPW4pKSzVyPUO0MlYxOzJizszN MWPTRW5ITVJ?
P12-ICHIKAWA MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33OfmlEPTB;M{SuO|Q6OSEQvF2= NYPncWhLW0GQR1XS
CAL-51 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nkWmlEPTB;M{WuNFcxQSEQvF2= Mn;0V2FPT0WU
Ramos-2G6-4C10 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrsbmdtUUN3ME2zOU4zPDJ3IN88US=> MWXTRW5ITVJ?
SCH Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\BTWM2OD1|Nj60NVc1KM7:TR?= MlHtV2FPT0WU
SK-MEL-24 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTGTGJNUUN3ME2zOk46ODR2IN88US=> MWDTRW5ITVJ?
SW1573 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfaS3NKSzVyPUO4MlczOTZizszN M{XPSHNCVkeHUh?=
BALL-1 M3O2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPNUo0xUUN3ME2zPU4zOTJ7IN88US=> MlPuV2FPT0WU
BE-13 M4n5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zCXmlEPTB;M{muN|I6KM7:TR?= M4rIO3NCVkeHUh?=
GI-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTN7Lki2OFch|ryP M4LVcXNCVkeHUh?=
GOTO M2Xtfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PBSGlEPTB;M{muPVE{QSEQvF2= M{\JU3NCVkeHUh?=
A673 M1jmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTRzLkCzOFMh|ryP NFvRN|dUSU6JRWK=
KG-1 M{TBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\uTWM2OD12Mz6zPVQh|ryP MWLTRW5ITVJ?
GP5d MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rybGlEPTB;NESuNFY3PiEQvF2= NYrOUWVzW0GQR1XS
MFM-223 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TOOmlEPTB;NESuNVIzQCEQvF2= MVXTRW5ITVJ?
OAW-42 M3[3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTR2LkK2OFMh|ryP NWfHWHZuW0GQR1XS
C8166 M1qyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS4TWM2OD12NT6wPFIzKM7:TR?= M2i1ZnNCVkeHUh?=
LU-99A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml32TWM2OD12Nj6xN|IzKM7:TR?= M1XZbnNCVkeHUh?=
NCI-H23 NWDabGxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7V[2ZxUUN3ME20Ok4yPzh3IN88US=> M4r2UnNCVkeHUh?=
HO-1-N-1 M{G2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzrclZKSzVyPUS3MlA6QThizszN MWjTRW5ITVJ?
A3-KAW NH33Z3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP4flhKSzVyPUS3MlExODdizszN MmLVV2FPT0WU
CGTH-W-1 M37ESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTR5LkWwOlkh|ryP NV\2dXQ6W0GQR1XS
DJM-1 NWPiWoZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHqeJU2UUN3ME20O{42PDF|IN88US=> M2WyXnNCVkeHUh?=
A101D NYHNRYxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP1TWM2OD12Nz62N|U4KM7:TR?= MVzTRW5ITVJ?
BB30-HNC M362Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTR6LkOwO|Ih|ryP MoHMV2FPT0WU
T98G Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D0W2lEPTB;NEiuOFY{OyEQvF2= M{OyTXNCVkeHUh?=
NCI-H1573 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fLNmlEPTB;NEmuOFQ3OiEQvF2= MUjTRW5ITVJ?
MEG-01 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjoWJFKSzVyPUS5Mlc1OTFizszN MYXTRW5ITVJ?
WM-115 NX3vSFZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDMdmhJUUN3ME20PU46OjJ{IN88US=> MXvTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 2:

    How long can the chemical compound be stable in DMEM at 4 ℃?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID